share_log

和黃醫藥：自願性公告－和黃醫藥將於美國臨床腫瘤學會 (ASCO) 2024年年會公佈數據

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

Hong Kong Stock Exchange ·  May 24 08:00
Summary by Futu AI
和黃醫藥（HUTCHMED）宣布將於2024年5月31日至6月4日在美國伊利諾伊州芝加哥舉行的美國臨床腫瘤學會（ASCO）年會上，公佈其自主研發的化合物的最新研究數據。其中包括呋喹替尼聯合信迪利單抗在子宮內膜癌患者中的II期註冊研究結果，該研究支持了在中國提交新藥上市申請。此外，將公佈FRUTIGA III期研究的關鍵亞組更新數據、FRESCO和FRESCO-2結直腸癌III期研究數據，以及ERK1/2抑制劑HMPL-295的初步臨床數據等。這些數據將有助於了解和黃醫藥在腫瘤治療領域的研究進展和臨床應用潛力。
和黃醫藥（HUTCHMED）宣布將於2024年5月31日至6月4日在美國伊利諾伊州芝加哥舉行的美國臨床腫瘤學會（ASCO）年會上，公佈其自主研發的化合物的最新研究數據。其中包括呋喹替尼聯合信迪利單抗在子宮內膜癌患者中的II期註冊研究結果，該研究支持了在中國提交新藥上市申請。此外，將公佈FRUTIGA III期研究的關鍵亞組更新數據、FRESCO和FRESCO-2結直腸癌III期研究數據，以及ERK1/2抑制劑HMPL-295的初步臨床數據等。這些數據將有助於了解和黃醫藥在腫瘤治療領域的研究進展和臨床應用潛力。
HUTCHMED ANNOUNCED THAT IT WILL ANNOUNCE THE LATEST STUDY DATA ON ITS INDEPENDENTLY DEVELOPED COMPOUND AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING HELD IN CHICAGO, ILLINOIS, USA, FROM MAY 31 TO JUNE 4, 2024. These include the results of a Phase II registration study of furoquintin-conjugated cindylisone in patients with endometrial cancer, which supported the submission of a new drug listing application in China. IN ADDITION, KEY SUBGROUP UPDATE DATA FOR FRUTIGA PHASE III STUDY, FRESCO AND FRESCO-2 COLORECTAL CANCER PHASE III STUDY DATA, AND PRELIMINARY CLINICAL DATA FOR ERK1/2 INHIBITOR HMPL-295, ETC., WILL BE ANNOUNCED. These data will help to understand the research progress and clinical application potential of yellow medicine in the field of oncology therapy.
HUTCHMED ANNOUNCED THAT IT WILL ANNOUNCE THE LATEST STUDY DATA ON ITS INDEPENDENTLY DEVELOPED COMPOUND AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING HELD IN CHICAGO, ILLINOIS, USA, FROM MAY 31 TO JUNE 4, 2024. These include the results of a Phase II registration study of furoquintin-conjugated cindylisone in patients with endometrial cancer, which supported the submission of a new drug listing application in China. IN ADDITION, KEY SUBGROUP UPDATE DATA FOR FRUTIGA PHASE III STUDY, FRESCO AND FRESCO-2 COLORECTAL CANCER PHASE III STUDY DATA, AND PRELIMINARY CLINICAL DATA FOR ERK1/2 INHIBITOR HMPL-295, ETC., WILL BE ANNOUNCED. These data will help to understand the research progress and clinical application potential of yellow medicine in the field of oncology therapy.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.